Table 1.

Summary of the clinical application of MSCs.

Disease	Sample Size	Study Period	Origin	Dosage	Injection	Reference
aGVHD	1	1 year	allogeneic BM MSCs	1, 2 × 106/kg	i.v.	[112]
aGVHD	55	60 months	allogeneic BM MSCs	1.4 × 106/kg	i.v.	[113]
aGVHD	12	427–1111 days	allogeneic BM MSCs	8 × 106/kg 2 × 106/kg	i.v.	[114]
aGVHD	75	2–1639 days	allogeneic BM MSCs	2 × 106/kg	i.v.	[115]
aGVHD	13	55–692 days	allogeneic BM MSCs	0.9 × 106/kg	i.v.	[116]
GVHD	11	4–18 months	allogeneic BM MSCs	1.2 × 106/kg	i.v.	[117]
CD	12	1 year	autogenous BM MSCs	2 × 107/kg	Lumen and the walls of the tracks	[118]
CD	16	6 weeks	allogeneic MSCs	2 × 106/kg	i.v.	[119]
CD	12	2 years	human placenta-MSCs	2, 5, 10 × 106/kg	i.v.	[120]
MS	10	13–26 months	autogenous BM MSCs	8.73 × 106/person	Intrathecally	[121]
MS	10	1 year	autogenous BM MSCs	3–5 × 107/person	The subarachnoid space	[122]
MS	10	20 months	autogenous BM MSCs	1.6 × 106/kg	i.v.	[123]
T1D	2	1 year	autogenous BM MSCs	180 × 106/kg	Liver puncture	[124]
T1D	20	1 year	autogenous BM MSCs	2.75 × 106/kg	i.v.	[125]
AD	34	1, 3 months	human UCB MSCs	2.5, 5 × 107/kg	Subcutaneously	[126]

aGVHD, acute graft versus host disease; CD, Crohn’s disease; MS: Multiple sclerosis; T1D: type 1 diabetes; AD: atopic dermatitis; i.v.: intravenously; BM MSCs: MSCs derived from bone marrow; UCB MSCs: MSCs derived from umbilical cord blood.